# Medicinal Cannabis in Advanced Cancer: What the New RESONANCE Trial Protocol Will Actually Test > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/resonance-trial-cannabis-cancer-protocol-advanced/ > **Published:** 2026-07-22T08:31:45-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:56:51-04:00 > **Clinical Summary:** Explore the RESONANCE trial cannabis cancer protocol, a Phase I/II study testing medicinal cannabis for quality of life and symptom control in advanced cancer. --- CED Clinical Relevance #68 Notable Protocol, No Outcomes Yet A protocol paper published July 20, 2026 in Clinical Therapeutics describes RESONANCE, a Phase I/II, multicenter, double-blind, randomized controlled trial of medicinal cannabis in people with advanced cancer, registered with the Australian New Zealand [Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Registry (ACTRN12619001534178). The paper itself reports no efficacy or safety results. Its relevance is that it is a real, methodologically serious trial designed to answer a question patients ask constantly and that current evidence has not settled. Clinical Insight | CED Clinic This is a trial protocol, not a results paper, and that distinction should govern how it gets used in conversation with patients. The authors state plainly that medicinal cannabis is increasingly used in cancer care despite limited high-quality evidence, and that legalization has outpaced the research needed to guide practice, leaving both patients and prescribers uncertain. RESONANCE responds to that gap with a two-phase design: an open-label Phase I to characterize safety, tolerability, and pharmacokinetics, followed by a double-blind, randomized, placebo-controlled Phase II measuring [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) and symptom control, including pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden, using validated instruments. No outcome data exists yet. Advanced CancerTrial Protocol[Quality of Life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/)Palliative CarePhase I/II Audience Oncology and palliative care clinicians, cannabis clinicians managing patients with advanced cancer, hospice and supportive care teams, researchers tracking registered cannabinoid trials, and patients with advanced cancer or their caregivers asking whether medicinal cannabis is being studied properly. Primary Topic A Phase I/II, multicenter, double-blind, randomized controlled trial protocol (RESONANCE) evaluating the safety, tolerability, and impact of medicinal cannabis on [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) and symptom control in people with advanced cancer. Source [Read the full PubMed record](https://pubmed.ncbi.nlm.nih.gov/42476829/) A newly published trial protocol describes RESONANCE, a two-phase study testing medicinal cannabis in people with advanced cancer. Phase I will establish safety, tolerability, and pharmacokinetics in an open-label design. Phase II will be a double-blind, randomized, placebo-controlled trial measuring quality of life and symptom control using validated instruments. No results exist yet. This is a protocol worth watching, not a treatment finding to act on. What This Study Teaches Us This protocol teaches how a rigorous trial addressing a real clinical uncertainty, whether medicinal cannabis meaningfully improves quality of life and symptom burden in advanced cancer, actually gets built: staged safety work before an efficacy question, validated outcome instruments instead of informal report, and a public trial registry entry that lets clinicians track the work before results appear. Why This Matters Advanced cancer patients raise cannabis with their oncology and palliative care teams routinely, and the honest answer today is that high-quality controlled evidence on quality of life and symptom outcomes remains limited relative to how widely cannabis is already used in this setting. A properly powered Phase I/II trial using validated quality-of-life and symptom instruments, rather than open-label case series or retrospective survey data, is the kind of study that could actually move the evidence base rather than add another anecdote to it. Study Snapshot Study Type Phase I/II, multicenter, double-blind, randomized, placebo-controlled trial protocol Phase I Design Open-label; evaluates safety profile, tolerability, and pharmacokinetic profile of medicinal cannabis Phase II Design Double-blind, randomized, placebo-controlled; evaluates quality of life and symptom control Phase II Outcome Domains Pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden, using validated instruments Population People with advanced cancer Trial Registry Australian New Zealand [Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Registry, ACTRN12619001534178 Journal Clinical Therapeutics Published July 20, 2026 (protocol paper; trial ongoing) PMID 42476829 DOI 10.1016/j.clinthera.2026.06.018 Results Status Not yet reported; this publication describes methodology only Clinical Bottom Line RESONANCE is a real, registered Phase I/II trial designed to test whether medicinal cannabis measurably improves quality of life and symptom control in advanced cancer, using a staged safety-first design and validated outcome instruments. The protocol paper itself contains no efficacy or safety results. It is worth tracking, not yet worth citing as evidence of benefit or harm. What the Protocol Actually Describes RESONANCE is a Phase I/II, multicenter trial. Phase I is open-label and is designed to determine the safety profile and tolerability of medicinal cannabis in people with advanced cancer by evaluating clinical outcomes and a pharmacokinetic profile. Phase II is a double-blind, randomized, placebo-controlled trial designed to determine the impact of medicinal cannabis on quality of life and symptom control, covering pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden, all measured with validated instruments. Why the Trial Was Designed This Way The authors state their rationale directly: medicinal cannabis is increasingly used in cancer care despite limited high-quality evidence to inform practice, and legalization has outpaced high-quality research on cancer symptom outcomes, leaving patients and prescribers with real uncertainty. A staged design, safety and pharmacokinetics first, then a randomized, blinded efficacy question, is the standard structure for building evidence responsibly rather than skipping to broad clinical claims. What a Protocol Paper Can and Cannot Tell You This publication is a trial protocol, not a results paper. It describes the design, population, phases, and outcome measures for a study that is underway; it does not report whether medicinal cannabis improved, worsened, or had no effect on any of the quality-of-life or symptom domains it plans to measure. Publications of this type are meant to be read as a description of the question being asked and how rigorously it will be tested, not as an early signal of the answer. Scale and Context, As the Authors Frame It The trial is multicenter, and the authors note that the findings have the potential to inform clinical practice and reduce decisional uncertainty for prescribers and patients, given the very large number of people who die of advanced cancer worldwide each year. That framing describes the trial’s intended significance if it succeeds. It is a statement of the question’s importance, not a claim that the trial has already demonstrated an effect at that scale. What to Watch For Next The next milestones to track are the Phase I safety, tolerability, and pharmacokinetic results, followed by the Phase II quality-of-life and symptom-control outcomes from the randomized, placebo-controlled comparison. The trial is listed on the Australian New Zealand [Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Registry under ACTRN12619001534178, which is the reference point for checking recruitment status and eventual results reporting. How Strong Is This Evidence? As a protocol, this paper’s strength lies in trial design rather than trial findings: a staged Phase I safety and pharmacokinetic evaluation followed by a double-blind, randomized, placebo-controlled Phase II using validated multi-domain quality-of-life and symptom instruments is a methodologically serious approach, publicly registered and peer-reviewed. It carries no evidence of efficacy or safety at this stage because no outcome data have been reported. Where This Paper Deserves Skepticism Protocol papers can be misread as early proof of concept simply because they were peer-reviewed and describe a well-designed study. Readers should be clear that RESONANCE has not yet reported whether medicinal cannabis is safe, tolerable, or effective for any of its target outcomes in advanced cancer, and that a favorable trial design does not guarantee a favorable or even a clear result once Phase I and Phase II data are analyzed. What This Paper Does Not Show This protocol does not show that medicinal cannabis improves quality of life, reduces pain, anorexia, anxiety, nausea, or caregiver burden, or is safe and well tolerated in advanced cancer. It reports no participant outcomes, no adverse event data, and no pharmacokinetic findings. It describes what will be tested and how, not what was found. How This Fits With the Broader Clinical Conversation [Medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use in advanced cancer and palliative care has expanded well ahead of controlled outcome data, a gap the authors name explicitly as their motivation for the trial. Protocol publications like this one are how that gap eventually gets closed, provided the subsequent Phase I and Phase II results are published and reviewed with the same scrutiny. A staged safety-then-efficacy design, using validated multi-domain instruments rather than a single symptom score, reflects a more rigorous standard than much of the existing observational literature on cannabis in cancer care. Dr. Caplan’s Take *Patients with advanced cancer ask me about cannabis constantly, usually after they have already started using it based on a friend’s experience or something they read online. What I want for them is not more anecdote; it is exactly this kind of staged, validated-instrument trial that treats their quality of life as something worth measuring rigorously rather than assuming.* *I will be watching for the Phase I safety and pharmacokinetic results first, because that is the responsible order, and I will not be citing this protocol as evidence of benefit to any patient in the meantime. A well-designed question is not the same as an answer.* What a Careful Reader Should Take Away A careful reader should take away that RESONANCE is a legitimate, peer-reviewed, publicly registered Phase I/II trial testing an important and currently underexamined clinical question, whether medicinal cannabis meaningfully improves quality of life and symptom control in advanced cancer, using a safety-first, validated-instrument design. No results exist yet, and none of this protocol should be read as evidence that medicinal cannabis works, is safe, or is unsafe in this population. Evidence Interpretation Guide Table of Contents - [How to Read a Trial Protocol Without Overstating What It Shows](#How_to_Read_a_Trial_Protocol_Without_Overstating_What_It_Shows)[Four questions to ask before summarizing this protocol](#Four_questions_to_ask_before_summarizing_this_protocol) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[A Real Trial Is Underway, But No Results Yet](#A_Real_Trial_Is_Underway_But_No_Results_Yet) - [Caregiver Burden Is an Explicit Outcome](#Caregiver_Burden_Is_an_Explicit_Outcome) - [A Staged, Well-Controlled Design](#A_Staged_Well-Controlled_Design) - [A Protocol Is Not a Finding](#A_Protocol_Is_Not_a_Finding) - [A Study to Track, Not Yet a Practice Change](#A_Study_to_Track_Not_Yet_a_Practice_Change) - [Phase I Results Are the Next Milestone](#Phase_I_Results_Are_the_Next_Milestone) - [Registered Trials Support Better Policy Debate](#Registered_Trials_Support_Better_Policy_Debate) - [Accurate Framing Prevents Premature Conclusions](#Accurate_Framing_Prevents_Premature_Conclusions) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read a Trial Protocol Without Overstating What It Shows A protocol paper is easy to overread because it was peer-reviewed, describes a real registered trial, and can sound like early validation of the treatment it studies. This paper is most useful when read as a description of a question being tested rigorously, not as a preview of the answer. ### Four questions to ask before summarizing this protocol **What was actually published?**A trial protocol describing design, phases, population, and outcome measures for RESONANCE, an ongoing Phase I/II study. No participant outcomes are reported. **Does the paper report results?**No. Phase I safety and pharmacokinetic data and Phase II quality-of-life and symptom-control data have not yet been published. **How rigorous is the planned design?**Phase I is open-label for safety and pharmacokinetics; Phase II is double-blind, randomized, and placebo-controlled, using validated instruments across eight symptom and quality-of-life domains. **What claim is actually justified right now?**The justified claim is that a serious, registered trial is underway to answer this question. It is not justified to claim medicinal cannabis has been shown to help, harm, or have no effect on quality of life or symptoms in advanced cancer. The Research Question Does medicinal cannabis improve quality of life and symptom control, without unacceptable safety or tolerability problems, in people with advanced cancer? The Patient Question Is there a real study testing whether medicinal cannabis actually helps people like me with advanced cancer, and are results available yet? The Bottom Line Yes, a real registered trial (RESONANCE) is testing this question with a rigorous design, but results are not available yet. This protocol describes the plan, not the findings. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Different readers will be tempted to treat a well-designed protocol as if it were already a positive result, or to dismiss it because it has not reported findings. These eight lenses keep the paper anchored to what a protocol publication actually is. #### A Real Trial Is Underway, But No Results Yet RESONANCE is a real, registered study testing whether medicinal cannabis improves quality of life and symptom control in advanced cancer, using validated instruments across pain, anorexia, anxiety, sleep, nausea, and other domains. No outcome data has been published yet, so this protocol cannot tell you whether cannabis will help your specific symptoms. Lens takeaway A well-designed trial question is not the same as a proven answer. #### Caregiver Burden Is an Explicit Outcome Unlike many cannabis studies, RESONANCE explicitly plans to measure caregiver burden alongside patient-reported pain, anorexia, anxiety, sleep, nausea, and treatment satisfaction, which reflects the realities of advanced cancer care. That inclusion is a design strength worth noting for palliative and hospice teams, even though the actual caregiver-burden findings are not yet available. Lens takeaway The planned outcome set reflects real palliative-care priorities, not just symptom scores. #### A Staged, Well-Controlled Design An open-label Phase I for safety and pharmacokinetics, followed by a double-blind, randomized, placebo-controlled Phase II with validated multi-domain instruments, is a methodologically serious structure for this question. The registration on the Australian New Zealand Clinical Trials Registry (ACTRN12619001534178) supports transparency and lets outside observers track whether results are eventually reported in full. Lens takeaway Strong planned design; the value depends on completed, transparently reported results. #### A Protocol Is Not a Finding A skeptical reader should notice that nothing in this paper demonstrates that medicinal cannabis helps, harms, or is neutral for any outcome in advanced cancer; it only describes how that question will be tested. Coverage that treats a protocol announcement as if it were a positive trial result is overstating the paper. Lens takeaway No outcome data means no efficacy or safety claim is yet justified. #### A Study to Track, Not Yet a Practice Change For clinicians fielding cannabis questions from advanced cancer patients today, this protocol supports acknowledging that rigorous research is underway without yet changing counseling or prescribing based on it. The registry identifier gives a concrete way to monitor recruitment and eventual results rather than relying on informal updates. Lens takeaway Track the registry; do not cite the protocol as practice evidence yet. #### Phase I Results Are the Next Milestone The logical next publication from this trial is the Phase I safety, tolerability, and pharmacokinetic data, which will determine whether and how the Phase II efficacy comparison proceeds as planned. Until Phase I and Phase II results are published, this protocol functions as a description of an open question, not an answer. Lens takeaway Watch for Phase I safety data first, then Phase II quality-of-life outcomes. #### Registered Trials Support Better Policy Debate Policy discussions about medicinal cannabis access in cancer care are often short on controlled outcome data. A registered, adequately designed trial like RESONANCE is the kind of evidence that could eventually inform those debates. Until results are published, this protocol should inform awareness that better evidence is being built, not settle any policy argument in either direction. Lens takeaway A registered trial is a step toward better evidence, not evidence itself yet. #### Accurate Framing Prevents Premature Conclusions Protocol papers are sometimes shared publicly in ways that imply a treatment has been validated. This paper is a clear example of why that framing is premature. Communicating clearly that RESONANCE has not yet reported results protects public understanding of where the evidence on cannabis in advanced cancer actually stands. Lens takeaway Precise framing of a protocol-only publication is itself a [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) service. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Medicinal+Cannabis+in+Advanced+Cancer%3A+What+the+New+RESONANCE+Trial+Protocol+Will+Actually+Test&url=https%3A%2F%2Fcedclinic.com%2Fmedicinal-cannabis-advanced-cancer-resonance-trial-protocol%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fmedicinal-cannabis-advanced-cancer-resonance-trial-protocol%2F) [BlueSky](https://bsky.app/intent/compose?text=Medicinal+Cannabis+in+Advanced+Cancer%3A+What+the+New+RESONANCE+Trial+Protocol+Will+Actually+Test%20https%3A%2F%2Fcedclinic.com%2Fmedicinal-cannabis-advanced-cancer-resonance-trial-protocol%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Wong AK, McMahon WR, Grobler A, Wilson C, Martin J, Galettis P, Mitchell P, Le B, Philip J, Gan H, Cebon J. Phase I/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol. Clin Ther. 2026 Jul 20.](https://pubmed.ncbi.nlm.nih.gov/42476829/) Related Reading at CED Clinic Continue exploring the evidence [Cannabinoids for Cancer Pain: New Review Questions the Opioid-Sparing Claim](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) An earlier CED review of cannabinoid evidence in cancer pain, useful context for how cautiously cancer-related cannabis claims should be read. [Read the cancer pain review context](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) [Dronabinol for Chronic Low Back Pain: What the Veterans Trial Will Actually Test](https://cedclinic.com/dronabinol-chronic-low-back-pain/) Another CED look at a registered cannabinoid trial protocol, useful for comparing how protocol-stage studies should be read before results exist. [Read the veterans trial protocol context](https://cedclinic.com/dronabinol-chronic-low-back-pain/) [Medical Cannabis for Chronic Pain: Function and Recovery](https://cedclinic.com/medical-cannabis-chronic-pain-function/) CED coverage of cannabis and functional outcomes in [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), relevant background for symptom-focused quality-of-life measurement in serious illness. [Read the chronic pain and function coverage](https://cedclinic.com/medical-cannabis-chronic-pain-function/) ## Frequently Asked Questions What is the RESONANCE trial? RESONANCE is a Phase I/II, multicenter, double-blind, randomized, placebo-controlled trial testing medicinal cannabis for quality of life and symptom control in people with advanced cancer, registered as ACTRN12619001534178. Has this trial reported results yet? No. The July 20, 2026 publication in Clinical Therapeutics is a trial protocol describing the study design, not a results paper. No efficacy or safety data have been reported. What will Phase I of the trial measure? Phase I is open-label and is designed to determine the safety profile, tolerability, and pharmacokinetic profile of medicinal cannabis in people with advanced cancer. What will Phase II of the trial measure? Phase II is a double-blind, randomized, placebo-controlled trial measuring quality of life and symptom control, including pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden, using validated instruments. Why was this trial designed in two phases? The authors describe a staged approach: establish safety and pharmacokinetics first in an open-label phase, then test the quality-of-life and symptom-control question in a blinded, randomized, placebo-controlled phase. Why did the researchers say this trial is needed? The authors state that medicinal cannabis is increasingly used in cancer care despite limited high-quality evidence, and that legalization has outpaced research on cancer symptom outcomes, creating uncertainty for patients and prescribers. Does this mean medicinal cannabis has been proven to help advanced cancer symptoms? No. This is a protocol paper describing planned methodology. It does not contain outcome data, so it cannot show whether medicinal cannabis helps, harms, or has no effect on cancer-related symptoms. Where is this trial registered? The trial is registered with the Australian New Zealand Clinical Trials Registry under identifier ACTRN12619001534178. Who is running the trial? The protocol was published by Wong, McMahon, Grobler, Wilson, Martin, Galettis, Mitchell, Le, Philip, Gan, and Cebon in Clinical Therapeutics. When might results be available? The protocol paper does not give a results timeline. Readers can track the Australian New Zealand Clinical Trials Registry entry (ACTRN12619001534178) for recruitment status and eventual results reporting. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).